JP2009536617A5 - - Google Patents

Download PDF

Info

Publication number
JP2009536617A5
JP2009536617A5 JP2009505430A JP2009505430A JP2009536617A5 JP 2009536617 A5 JP2009536617 A5 JP 2009536617A5 JP 2009505430 A JP2009505430 A JP 2009505430A JP 2009505430 A JP2009505430 A JP 2009505430A JP 2009536617 A5 JP2009536617 A5 JP 2009536617A5
Authority
JP
Japan
Prior art keywords
aliphatic
compound
disease
formula
halo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009505430A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009536617A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/008819 external-priority patent/WO2007117692A2/en
Publication of JP2009536617A publication Critical patent/JP2009536617A/ja
Publication of JP2009536617A5 publication Critical patent/JP2009536617A5/ja
Pending legal-status Critical Current

Links

JP2009505430A 2006-04-11 2007-04-11 タンパク質キナーゼの阻害剤として有用なチアゾール、イミダゾール、およびピラゾール Pending JP2009536617A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US79108306P 2006-04-11 2006-04-11
PCT/US2007/008819 WO2007117692A2 (en) 2006-04-11 2007-04-11 Thiazoles, imidazoles, and pyrazoles useful as inhibitors of protein kinases

Publications (2)

Publication Number Publication Date
JP2009536617A JP2009536617A (ja) 2009-10-15
JP2009536617A5 true JP2009536617A5 (https=) 2011-05-12

Family

ID=38508761

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009505430A Pending JP2009536617A (ja) 2006-04-11 2007-04-11 タンパク質キナーゼの阻害剤として有用なチアゾール、イミダゾール、およびピラゾール

Country Status (9)

Country Link
US (3) US7589214B2 (https=)
EP (1) EP2007732B1 (https=)
JP (1) JP2009536617A (https=)
CN (1) CN101460466B (https=)
AT (1) ATE534632T1 (https=)
AU (1) AU2007235237B2 (https=)
CA (1) CA2648923A1 (https=)
ES (1) ES2376765T3 (https=)
WO (1) WO2007117692A2 (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2648923A1 (en) * 2006-04-11 2007-10-18 Vertex Pharmaceuticals Incorporated Thiazoles, imidazoles, and pyrazoles useful as inhibitors of protein kinases
MX2011011136A (es) * 2009-04-24 2011-11-18 Tibotec Pharm Ltd Eteres diarilicos.
EP2512246B1 (en) 2009-12-17 2015-09-30 Merck Sharp & Dohme Corp. Aminopyrimidines as syk inhibitors
KR101445012B1 (ko) 2009-12-17 2014-09-26 머크 샤프 앤드 돔 코포레이션 Syk 억제제로서의 아미노피리미딘
US9145391B2 (en) 2011-05-10 2015-09-29 Merck Sharp & Dohme Corp. Bipyridylaminopyridines as Syk inhibitors
EP2706853B1 (en) 2011-05-10 2017-06-14 Merck Sharp & Dohme Corp. Aminopyrimidines as syk inhibitors
CA2834062A1 (en) 2011-05-10 2012-11-15 Merck Sharp & Dohme Corp. Pyridyl aminopyridines as syk inhibitors
MX340033B (es) 2011-12-28 2016-06-21 Janssen Sciences Ireland Uc Derivados heterobiciclicos como inhibidores del virus de la hepatitis c.
SG11201500499TA (en) 2012-08-10 2015-03-30 Boehringer Ingelheim Int Heteroaromatic compounds as bruton's tyrosine kinase (btk) inhibitors
KR101668574B1 (ko) 2012-11-02 2016-10-24 화이자 인코포레이티드 브루톤 티로신 키나제 억제제
CN103848810A (zh) 2012-11-30 2014-06-11 北京赛林泰医药技术有限公司 鲁顿酪氨酸激酶抑制剂
JP6403751B2 (ja) 2013-03-14 2018-10-10 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 5−チアゾールカルボキサミン誘導体及びbtk阻害剤としてのその使用
JP6495886B2 (ja) 2013-03-15 2019-04-03 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Btk阻害剤としての複素環式芳香族化合物
KR102272792B1 (ko) 2013-09-30 2021-07-05 광저우 이노케어 파마 테크 씨오., 엘티디. Btk의 치환된 니코틴이미드 저해제 및 그의 제조 방법 및 암, 염증 및 자가면역 질환에의 용도
RU2653504C2 (ru) 2013-12-13 2018-05-10 Ф. Хоффманн-Ля Рош Аг Ингибиторы тирозинкиназы брутона
JP6486954B2 (ja) * 2014-01-29 2019-03-20 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Btk阻害剤としてのピラゾール化合物
CN105085474B (zh) * 2014-05-07 2018-05-18 北京赛林泰医药技术有限公司 鲁顿酪氨酸激酶抑制剂
CN106687446B (zh) * 2014-07-18 2020-04-28 百济神州(北京)生物科技有限公司 作为t790m/wt-egfr的选择性和不可逆的激酶抑制剂的5-氨基-4-氨甲酰基-吡唑化合物及其用途
LT3390390T (lt) 2015-12-16 2021-11-25 Boehringer Ingelheim International Gmbh Bipirazolilo dariniai, tinkami naudoti autoimuninių ligų gydymui
US10570118B2 (en) 2016-01-13 2020-02-25 Boehringer Ingelheim International Gmbh Isoquinolones as BTK inhibitors
AU2020229919B2 (en) 2019-02-25 2025-06-05 Beijing Innocare Pharma Tech Co., Ltd. Process for preparing 6- (1-Acryloylpiperidin-4-yl) -2- (4-phenoxyphenyl) nicotinamide
CN116018138B (zh) * 2020-07-13 2025-08-15 河南知微生物医药有限公司 作为布鲁诺酪氨酸激酶抑制剂的取代的1H-咪唑并[1,2-b]吡唑-3-甲酰胺

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9608435D0 (en) * 1996-04-24 1996-06-26 Celltech Therapeutics Ltd Chemical compounds
US6288061B1 (en) * 1997-12-26 2001-09-11 Welfide Corporation Imidazole derivatives
WO2002022605A1 (en) * 2000-09-15 2002-03-21 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
ES2274005T3 (es) * 2001-01-26 2007-05-16 Chugai Seiyaku Kabushiki Kaisha Inhibidores de malonyl-coa decarboxilasa usados como moduladores metabolicos.
CA2532965C (en) 2003-07-22 2013-05-14 Astex Therapeutics Limited 3, 4-disubstituted 1h-pyrazole compounds and their use as cyclin dependent kinases (cdk) and glycogen synthase kinase-3 (gsk-3) modulators
WO2005123671A1 (ja) * 2004-06-22 2005-12-29 Taisho Pharmaceutical Co., Ltd. ピロール誘導体
FR2881426B1 (fr) 2005-02-03 2007-03-30 Aventis Pharma Sa Pyrolles et imidazoles substitues, compositions les contenant, procede de frabrication et utilisation
CA2648923A1 (en) * 2006-04-11 2007-10-18 Vertex Pharmaceuticals Incorporated Thiazoles, imidazoles, and pyrazoles useful as inhibitors of protein kinases

Similar Documents

Publication Publication Date Title
JP2009536617A5 (https=)
EP3209656B1 (en) Indole carboxamides compounds useful as kinase inhibitors
ES2543216T3 (es) Moduladores de tiazolopirimidina como agentes inmunosupresores
ES2935633T3 (es) Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos
JP2023532257A5 (https=)
EA028079B1 (ru) Определенные аминопиримидины, композиции на их основе и способы их использования
CN113423685A (zh) 整合应激通路的前药调节剂
JP2020528889A5 (https=)
KR20250025475A (ko) 아미노피리미딘 유도체 또는 이의 염을 포함하는 경구 투여용 약학 조성물
JP2022526854A (ja) ホスファチジルイノシトール3-キナーゼ阻害剤
KR20090013804A (ko) 할로아릴 치환된 아미노퓨린, 이의 조성물 및 이를 이용한 치료 방법
JP2016538257A5 (https=)
CN108553467A (zh) 改善膈肌功能的方法
TW201106951A (en) 3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]octane-or heptane-nitrile as JAK inhibitors
JP2013502431A5 (https=)
WO2017025814A1 (en) Methods of treating cancers, immune and autoimmune diseases, and inflammatory diseases based on btk occupancy and btk resynthesis rate
CN101945655A (zh) 作为p2x7调节剂的5-氧代-3-吡咯烷甲酰胺衍生物
TW201917126A (zh) 二氫二酮
JP7672372B2 (ja) 4-アミノ-n-(1-((3-クロロ-2-フルオロフェニル)アミノ)-6-メチルイソキノリン-5-イル)チエノ[3,2-d]ピリミジン-7-カルボキサミドの塩とその結晶形態
JP6655608B2 (ja) 6−((6,7−ジメトキシキナゾリン−4−イル)オキシ)−n,2−ジメチルベンゾフラン−3−カルボキサミドの結晶形
JP7025555B2 (ja) 一過性受容体電位a1イオンチャネルの阻害
JP2019512534A5 (https=)
CA3176994A1 (en) Treatments of inflammatory bowel disease
CN105813643A (zh) 利用含有噻吩并三唑二氮杂*化合物的药物制剂治疗非小细胞肺癌的方法
US20200009175A1 (en) Nucleobase analogue derivatives and their applications